

Medsafe consultation submission

Addition of warn miconazole-conta	ing statements on ining medicines	labels of topi	cal		
Name and designation					
Company/organisation name and address					
Contact phone number and email address					
I would like the comments I have p specific sections of response if app	olicable)		lentify	☐ Yes ☐ No	
(Reasons for requesting confidentiality must meet Official Information Act 1982 criteria) I would like my name to be removed from all documents prior to publication on the Medsafe website.					
I would like for my name not to be included within the list of submissions published on the Medsafe website.			Yes No		
It would help in the analysis of stakeholder comments if you provide the information requested below.					
I am, or I represent, an org	anisation that is based in:				
☐ New Zealand ☐ Australia ☐ Other (please specify):					
I am, or I represent, a: (tick al.	l that apply)				
☐ Importer	☐ Manufacturer	Supplier	Sponsor		
Government	Researcher	☐ Professional body	☐ Industry organisation		
☐ Consumer organisation	☐ Member of the public	☐ Institution (e.g. university, hospital)			
☐ Regulatory affairs consultant	☐ Laboratory professional				
☐ Health professional – please indicate type of practice:					
☐ Other - please specify:					

Please return this form to:

Email: medsafeapplications@moh.govt.nz including 'Miconazole warning statements' in the subject line

Or Post: Product Regulation

Medsafe PO Box 5013 Wellington 6145

Medsafe is seeking comments on:			
Whether a warning statement about the interaction between warfarin and miconazole is required for all topical miconazole containing medicines available without prescription.			
- If a warning is not required for all products please provide your reasoning			
Which of the proposed warning statements about the interaction between warfarin and miconazole is preferred?			
 Please provide your reasoning, this will help Medsafe when considering future warning statements 			

Please include additional pages if necessary.

Whether the statements required in Australia for intravaginal miconazole products should be included in the Label Statements Database.		
- Please provide your reasoning		
- Are the statements acceptable or should they be reworded?		
What is a suitable target date for implementation:		
- Please provide justification		